» Articles » PMID: 22252512

Preventing Spontaneous Genetic Rearrangements in the Transgene Cassettes of Adenovirus Vectors

Overview
Publisher Wiley
Specialty Biochemistry
Date 2012 Jan 19
PMID 22252512
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

First-generation, E1/E3-deleted adenoviral vectors with diverse transgenes are produced routinely in laboratories worldwide for development of novel prophylactics and therapies for a variety of applications, including candidate vaccines against important infectious diseases, such as HIV/AIDS, tuberculosis, and malaria. Here, we show, for two different transgenes (both encoding malarial antigens) inserted at the E1 locus, that rare viruses containing a transgene-inactivating mutation exhibit a selective growth advantage during propagation in E1-complementing HEK293 cells, such that they rapidly become the major or sole species in the viral population. For one of these transgenes, we demonstrate that viral yield and cytopathic effect are enhanced by repression of transgene expression in the producer cell line, using the tetracycline repressor system. In addition to these transgene-inactivating mutations, one of which occurred during propagation of the pre-viral genomic clone in bacteria, and the other after viral reconstitution in HEK293 cells, we describe two other types of mutation, a small deletion and a gross rearranging duplication, in one of the transgenes studied. These were of uncertain origin, and the effects on transgene expression and viral growth were not fully characterized. We demonstrate that, together with minor protocol modifications, repression of transgene expression in HEK293 cells during viral propagation enables production of a genetically stable chimpanzee adenovirus vector expressing a malarial antigen which had previously been impossible to derive. These results have important implications for basic and pre-clinical studies using adenoviral vectors and for derivation of adenoviral vector products destined for large-scale amplification during biomanufacture.

Citing Articles

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.

ODonnell K, Henderson C, Anhalt H, Fusco J, Erasmus J, Lambe T Int J Mol Sci. 2024; 25(15).

PMID: 39126087 PMC: 11313278. DOI: 10.3390/ijms25158516.


Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.

Bissett C, Belij-Rammerstorfer S, Ulaszewska M, Smith H, Kailath R, Morris S NPJ Vaccines. 2024; 9(1):118.

PMID: 38926455 PMC: 11208422. DOI: 10.1038/s41541-024-00912-1.


Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.

Neckermann P, Mohr M, Billmeier M, Karlas A, Boilesen D, Thirion C Front Immunol. 2024; 15:1338492.

PMID: 38380318 PMC: 10877035. DOI: 10.3389/fimmu.2024.1338492.


ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T, Mendonca L, Zhu Y, Howe A, Radecke J, Shah P iScience. 2023; 26(10):107882.

PMID: 37766989 PMC: 10520439. DOI: 10.1016/j.isci.2023.107882.


Partial Disturbance of Microprocessor Function in Human Stem Cells Carrying a Heterozygous Mutation in the DGCR8 Gene.

Ree D, Fothi A, Varga N, Kolacsek O, Orban T, Apati A Genes (Basel). 2022; 13(11).

PMID: 36360162 PMC: 9689658. DOI: 10.3390/genes13111925.


References
1.
Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

2.
Umenhoffer K, Feher T, Baliko G, Ayaydin F, Posfai J, Blattner F . Reduced evolvability of Escherichia coli MDS42, an IS-less cellular chassis for molecular and synthetic biology applications. Microb Cell Fact. 2010; 9:38. PMC: 2891674. DOI: 10.1186/1475-2859-9-38. View

3.
Hermening S, Kugler S, Bahr M, Isenmann S . Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron sequence. J Virol Methods. 2004; 122(1):73-7. DOI: 10.1016/j.jviromet.2004.08.005. View

4.
Xiang Z, Yang Y, Wilson J, Ertl H . A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 1996; 219(1):220-7. DOI: 10.1006/viro.1996.0239. View

5.
Williamson K . Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol. 2003; 25(7):351-9. DOI: 10.1046/j.1365-3024.2003.00643.x. View